CVBT OVERVIEW
Our Approach in Science and Technology:
CardioVascular BioTherapeutics, Inc. (CVBT) is a development stage biopharmaceutical company advancing biologic drug candidates to address diseases such as diabetic wounds, severe ischemic heart disease, peripheral artery disease, erectile dysfunction and infarct stroke. CVBT is focused on research & development aimed at improving the quality of life for those suffering from ischemic tissue and organs.
In The News
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate stimulates the growth of new blood vessels when administered to ischemic organs and tissues. These anatomical targets are shown in our pipeline section.
Peter Jennings - ABC World News report on CVBT’s Phase 1 Heart Trial with company doctors
An estimated 92,100,000 American adults (more than 1 in 3) have one or more types of cardiovascular disease (CVD). 2,300 Americans die of CVD each day, an average of one death every 38 seconds.
American Heart Association, "Heart Disease and Stroke Statistics-2018 Update"